| Literature DB >> 27677463 |
Joydeep Das1, Yun-Jung Choi1, Hideyo Yasuda1, Jae Woong Han1, Chankyu Park1, Hyuk Song1, Hojae Bae2, Jin-Hoi Kim1.
Abstract
The controlled differentiation of stem cells via the delivery of specific genes encoding appropriate differentiation factors may provide useful models for regenerative medicine and aid in developing therapies forEntities:
Year: 2016 PMID: 27677463 PMCID: PMC5039411 DOI: 10.1038/srep33784
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of nanoparticles.
(a) Schematic presentation and TEM image of AuPEINPs. (c) Particle diameter distribution of AuPEINPs. (b) Schematic presentation and TEM image of AuMUAPEINPs. (d) Particle diameter distribution of AuMUAPEINPs. (e) Weight loss curves (TGA) of AuPEINPs and AuMUAPEINPs.
Figure 2Agarose gel retardation assay.
(a) AuPEINPs-pDNA complexes were prepared at different ratios of particle numbers to 1 μg of pDNA. (b) AuMUAPEINPs-pDNA complexes were prepared at different ratios of particle numbers to 1 μg of pDNA. M: DNA marker. The number of nanoparticles used is shown on the top of each lane.
Figure 3Gene transfection efficiency measurements.
(a,b) Transfection efficiency of AuPEINPs and AuMUAPEINPs measured by luciferase reporter assays. All values are expressed as mean ± SD. (c) Fluorescence micrographs of cells transfected with pEGFP-C/EBPβ. (d) Quantification of GFP-positive cells by flow cytometry analysis. Values are expressed as mean ± SD. (e) Western blot analysis of GFP and C/EBPB proteins 48 h after transfection with pEGFP-C/EBPβ. Densitometric analyses were performed using Image J software, and intensity values were normalized with respect to β-actin. 1 μg of pDNA was used for all transfection experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 versus Lipofectamine 2000 transfected group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus PEI transfected group.
Figure 4Oil Red O staining and gene expression of adipogenic differentiation markers 7 days after transfecting the C/EBPβ gene.
(a) Oil Red O staining of non-treated control cells cultured in growth media. (b) Oil Red O staining of non-treated control cells cultured in ADM. (c) Oil Red O staining of cells expressing the C/EBPβ gene transfected with Lipofectamine 2000 and cultured in ADM. (d) and (e) Oil Red O staining of cells expressing the C/EBPβ gene transfected with AuPEINPs (1.06 × 1011 and 1.33 × 1011 number of particles, respectively) and cultured in ADM. (f) and (g) Oil Red O staining of cells expressing the C/EBPβ gene transfected with AuMUAPEINPs (0.35 × 1011 and 0.53 × 1011 number of particles, respectively) and cultured in ADM. (h) Quantitative analysis of lipid droplet formation. (i–k) qRT-PCR analysis of the relative mRNA expressions of C/EBPβ, PPARγ2, and AP2 in cells transfected with the C/EBPβ gene and cultured in ADM. All values are expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the control non-transfected group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus Lipofectamine transfected group.
Figure 5Cellular localization and quantitative determination of cellular uptake of nanoparticle-DNA complexes.
(a) TEM analysis of control non-treated cells. (b,c) TEM analysis for cellular localization of AuPEINPs-pDNA and AuMUAPEINPs-pDNA complexes. M: mitochondria; N: nuclei; C: cytoplasm; AV: autophagic vesicles; DMA: double-membrane autophagosomes; L: lysosomes; MI: membrane integrity; ER: endoplasmic reticulum; pink arrow: nanoparticle/DNA complexes. (d) The number of nanoparticles internalized per cell determined by ICP-MS. (e) % uptake efficiency of nanoparticles into cells. All values are expressed as mean ± SD.
Figure 6Intracellular distribution and cellular uptake pathways of nanoparticle-DNA complexes.
(a) Confocal micrographs of the intracellular distribution and localization of gold nanoparticle-Cy3-DNA complexes 12 h after transfection. Green regions indicate lysosomes and endosomes stained with LysoTracker Green. Red regions indicate Cy3-DNA. Yellow regions indicate co-localization of nanoparticle-Cy3-DNA complexes with endosomes/lysosomes. (b) The mechanism of cellular uptake of gold nanoparticle-pDNA complexes by hMSCs was investigated by pretreating cells with several endocytosis inhibitors prior to transfecting with the Luc gene. Cells were either cultured at 37 °C as a negative control (Cont) or pretreated with MBCD, chlorpromazine, or LY294002. All values are expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the non-treated control group.
Figure 7Cell viability assay.
Cell viability relative to the untreated control (100%) in hMSCs cells. Cells were treated with different concentrations of AuPEINPs-pEGFP-C/EBPβ and AuMUAPEINPs- pEGFP-C/EBPβ complexes for 6 h and cell viability was measured after 48 h (a), 72 h (b) and 96 h (c) using the Cell Counting Kit-8 (CCK-8). All values are expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the non-treated control group. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus the PEI-treated group. @p < 0.05, @@p < 0.01, and @@@p < 0.001 versus the Lipofectamine -treated group.